Basal insulin treatment is the cornerstone of type 1 diabetes management and often becomes necessary over time in type 2 diabetes as the disease progresses. 

Basal insulins are administered once or twice daily; however, there is potential added value from a once-weekly insulin to reduce treatment burden. 

Insulin icodec (icodec) is one of two once-weekly insulins in late phase clinical development. Icodec is an insulin analogue with three substitutions to the amino acid structure and an attached C20 icosane fatty diacid chain that allows the molecule to bind reversibly to albumin, prolonging the half-life to 196 h (approximately 7 days) and achieving steady state after 3–4 once-weekly injections.1

Read more here.

References

  1. Shah, A. S., & Wolf, R. M. (2023). Weekly insulin: a paradigm shift in type 1 diabetes therapy. The Lancet, 402(10413), 1598–1599. https://doi.org/10.1016/s0140-6736(23)02227-4

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred